nodes	percent_of_prediction	percent_of_DWPC	metapath
Aprepitant—Cytochrome P450 3A4 Inhibitors—Cyclosporine—systemic lupus erythematosus	0.395	1	CiPCiCtD
Aprepitant—colon cancer—Betamethasone—systemic lupus erythematosus	0.123	0.366	CpDpCtD
Aprepitant—colon cancer—Dexamethasone—systemic lupus erythematosus	0.123	0.366	CpDpCtD
Aprepitant—breast cancer—Dexamethasone—systemic lupus erythematosus	0.0451	0.134	CpDpCtD
Aprepitant—breast cancer—Betamethasone—systemic lupus erythematosus	0.0451	0.134	CpDpCtD
Aprepitant—CYP3A7—Dapsone—systemic lupus erythematosus	0.013	0.0674	CbGbCtD
Aprepitant—CYP3A7-CYP3A51P—Dapsone—systemic lupus erythematosus	0.013	0.0674	CbGbCtD
Aprepitant—CYP1A2—Leflunomide—systemic lupus erythematosus	0.0102	0.0528	CbGbCtD
Aprepitant—CYP3A5—Dapsone—systemic lupus erythematosus	0.00973	0.0506	CbGbCtD
Aprepitant—CYP2C9—Leflunomide—systemic lupus erythematosus	0.00915	0.0476	CbGbCtD
Aprepitant—CYP3A7-CYP3A51P—Hydrocortisone—systemic lupus erythematosus	0.00902	0.0469	CbGbCtD
Aprepitant—CYP3A7—Hydrocortisone—systemic lupus erythematosus	0.00902	0.0469	CbGbCtD
Aprepitant—CYP3A7-CYP3A51P—Cyclosporine—systemic lupus erythematosus	0.00852	0.0443	CbGbCtD
Aprepitant—CYP3A7—Cyclosporine—systemic lupus erythematosus	0.00852	0.0443	CbGbCtD
Aprepitant—CYP3A5—Mycophenolate mofetil—systemic lupus erythematosus	0.00843	0.0438	CbGbCtD
Aprepitant—CYP2C19—Dapsone—systemic lupus erythematosus	0.00785	0.0408	CbGbCtD
Aprepitant—CYP3A5—Hydrocortisone—systemic lupus erythematosus	0.00677	0.0352	CbGbCtD
Aprepitant—CYP2C9—Dapsone—systemic lupus erythematosus	0.00652	0.0339	CbGbCtD
Aprepitant—CYP3A5—Cyclosporine—systemic lupus erythematosus	0.00639	0.0332	CbGbCtD
Aprepitant—CYP3A7-CYP3A51P—Dexamethasone—systemic lupus erythematosus	0.00561	0.0292	CbGbCtD
Aprepitant—CYP3A7—Dexamethasone—systemic lupus erythematosus	0.00561	0.0292	CbGbCtD
Aprepitant—CYP2C19—Prednisone—systemic lupus erythematosus	0.00544	0.0283	CbGbCtD
Aprepitant—CYP2C19—Cyclosporine—systemic lupus erythematosus	0.00516	0.0268	CbGbCtD
Aprepitant—CYP3A4—Methylprednisolone—systemic lupus erythematosus	0.00434	0.0226	CbGbCtD
Aprepitant—CYP2C9—Cyclosporine—systemic lupus erythematosus	0.00429	0.0223	CbGbCtD
Aprepitant—CYP3A5—Dexamethasone—systemic lupus erythematosus	0.00421	0.0219	CbGbCtD
Aprepitant—CYP3A4—Dapsone—systemic lupus erythematosus	0.00379	0.0197	CbGbCtD
Aprepitant—CYP2C9—cardial valve—systemic lupus erythematosus	0.00356	0.24	CbGeAlD
Aprepitant—CYP2C19—Dexamethasone—systemic lupus erythematosus	0.00339	0.0177	CbGbCtD
Aprepitant—CYP3A4—Triamcinolone—systemic lupus erythematosus	0.00329	0.0171	CbGbCtD
Aprepitant—CYP3A4—Mycophenolate mofetil—systemic lupus erythematosus	0.00329	0.0171	CbGbCtD
Aprepitant—CYP2C9—Dexamethasone—systemic lupus erythematosus	0.00282	0.0147	CbGbCtD
Aprepitant—CYP3A4—Betamethasone—systemic lupus erythematosus	0.00282	0.0147	CbGbCtD
Aprepitant—CYP3A4—Prednisolone—systemic lupus erythematosus	0.00278	0.0145	CbGbCtD
Aprepitant—CYP3A4—Hydrocortisone—systemic lupus erythematosus	0.00264	0.0137	CbGbCtD
Aprepitant—CYP3A4—Prednisone—systemic lupus erythematosus	0.00263	0.0137	CbGbCtD
Aprepitant—CYP3A4—Cyclosporine—systemic lupus erythematosus	0.00249	0.013	CbGbCtD
Aprepitant—CYP3A4—Dexamethasone—systemic lupus erythematosus	0.00164	0.00853	CbGbCtD
Aprepitant—TACR3—nervous system—systemic lupus erythematosus	0.00104	0.07	CbGeAlD
Aprepitant—TACR3—central nervous system—systemic lupus erythematosus	0.001	0.0674	CbGeAlD
Aprepitant—CYP2C19—urine—systemic lupus erythematosus	0.00099	0.0667	CbGeAlD
Aprepitant—CYP1A2—urine—systemic lupus erythematosus	0.000809	0.0545	CbGeAlD
Aprepitant—CYP2C9—urine—systemic lupus erythematosus	0.000767	0.0517	CbGeAlD
Aprepitant—TACR1—connective tissue—systemic lupus erythematosus	0.00072	0.0485	CbGeAlD
Aprepitant—CYP3A4—urine—systemic lupus erythematosus	0.000585	0.0394	CbGeAlD
Aprepitant—CYP2C19—blood plasma—systemic lupus erythematosus	0.000517	0.0348	CbGeAlD
Aprepitant—CYP3A7-CYP3A51P—nephron tubule—systemic lupus erythematosus	0.000507	0.0342	CbGeAlD
Aprepitant—TACR1—lung—systemic lupus erythematosus	0.000434	0.0293	CbGeAlD
Aprepitant—CYP3A7-CYP3A51P—cortex of kidney—systemic lupus erythematosus	0.000434	0.0292	CbGeAlD
Aprepitant—CYP1A2—blood plasma—systemic lupus erythematosus	0.000422	0.0284	CbGeAlD
Aprepitant—CYP3A5—blood plasma—systemic lupus erythematosus	0.000407	0.0274	CbGeAlD
Aprepitant—TACR1—nervous system—systemic lupus erythematosus	0.000402	0.0271	CbGeAlD
Aprepitant—CYP2C9—blood plasma—systemic lupus erythematosus	0.000401	0.027	CbGeAlD
Aprepitant—TACR1—central nervous system—systemic lupus erythematosus	0.000387	0.0261	CbGeAlD
Aprepitant—CYP3A4—blood plasma—systemic lupus erythematosus	0.000305	0.0206	CbGeAlD
Aprepitant—CYP3A5—nephron tubule—systemic lupus erythematosus	0.00021	0.0141	CbGeAlD
Aprepitant—CYP3A5—kidney—systemic lupus erythematosus	0.000184	0.0124	CbGeAlD
Aprepitant—CYP3A5—cortex of kidney—systemic lupus erythematosus	0.00018	0.0121	CbGeAlD
Aprepitant—CYP3A4—kidney—systemic lupus erythematosus	0.000138	0.00933	CbGeAlD
Aprepitant—CYP1A2—lung—systemic lupus erythematosus	0.000136	0.00913	CbGeAlD
Aprepitant—CYP3A5—lung—systemic lupus erythematosus	0.000131	0.00881	CbGeAlD
Aprepitant—CYP3A4—nervous system—systemic lupus erythematosus	9.08e-05	0.00612	CbGeAlD
Aprepitant—CYP3A4—central nervous system—systemic lupus erythematosus	8.75e-05	0.00589	CbGeAlD
Aprepitant—TACR1—Spinal Cord Injury—CCL2—systemic lupus erythematosus	3.55e-05	0.00616	CbGpPWpGaD
Aprepitant—TACR1—GPCR ligand binding—P2RY12—systemic lupus erythematosus	3.52e-05	0.00609	CbGpPWpGaD
Aprepitant—TACR3—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic lupus erythematosus	3.33e-05	0.00578	CbGpPWpGaD
Aprepitant—CYP2C19—Constitutive Androstane Receptor Pathway—RXRA—systemic lupus erythematosus	3.32e-05	0.00576	CbGpPWpGaD
Aprepitant—TACR3—GPCR ligand binding—CCR5—systemic lupus erythematosus	3.32e-05	0.00575	CbGpPWpGaD
Aprepitant—TACR3—GPCR ligand binding—C3—systemic lupus erythematosus	3.24e-05	0.00562	CbGpPWpGaD
Aprepitant—Fatigue—Hydrocortisone—systemic lupus erythematosus	3.24e-05	0.000578	CcSEcCtD
Aprepitant—Urethral disorder—Methotrexate—systemic lupus erythematosus	3.23e-05	0.000575	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Triamcinolone—systemic lupus erythematosus	3.23e-05	0.000575	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Methylprednisolone—systemic lupus erythematosus	3.22e-05	0.000574	CcSEcCtD
Aprepitant—Pain—Hydrocortisone—systemic lupus erythematosus	3.22e-05	0.000573	CcSEcCtD
Aprepitant—Oedema—Dexamethasone—systemic lupus erythematosus	3.22e-05	0.000573	CcSEcCtD
Aprepitant—Oedema—Betamethasone—systemic lupus erythematosus	3.22e-05	0.000573	CcSEcCtD
Aprepitant—Anaphylactic shock—Dexamethasone—systemic lupus erythematosus	3.22e-05	0.000573	CcSEcCtD
Aprepitant—Anaphylactic shock—Betamethasone—systemic lupus erythematosus	3.22e-05	0.000573	CcSEcCtD
Aprepitant—Insomnia—Triamcinolone—systemic lupus erythematosus	3.2e-05	0.000571	CcSEcCtD
Aprepitant—Insomnia—Methylprednisolone—systemic lupus erythematosus	3.2e-05	0.00057	CcSEcCtD
Aprepitant—Infection—Dexamethasone—systemic lupus erythematosus	3.19e-05	0.000569	CcSEcCtD
Aprepitant—Infection—Betamethasone—systemic lupus erythematosus	3.19e-05	0.000569	CcSEcCtD
Aprepitant—Ill-defined disorder—Prednisone—systemic lupus erythematosus	3.18e-05	0.000567	CcSEcCtD
Aprepitant—Paraesthesia—Triamcinolone—systemic lupus erythematosus	3.18e-05	0.000567	CcSEcCtD
Aprepitant—Feeling abnormal—Prednisolone—systemic lupus erythematosus	3.18e-05	0.000566	CcSEcCtD
Aprepitant—TACR1—Peptide ligand-binding receptors—CCR5—systemic lupus erythematosus	3.17e-05	0.0055	CbGpPWpGaD
Aprepitant—Paraesthesia—Methylprednisolone—systemic lupus erythematosus	3.17e-05	0.000566	CcSEcCtD
Aprepitant—Anaemia—Prednisone—systemic lupus erythematosus	3.17e-05	0.000565	CcSEcCtD
Aprepitant—Shock—Dexamethasone—systemic lupus erythematosus	3.16e-05	0.000563	CcSEcCtD
Aprepitant—Shock—Betamethasone—systemic lupus erythematosus	3.16e-05	0.000563	CcSEcCtD
Aprepitant—Dyspnoea—Triamcinolone—systemic lupus erythematosus	3.16e-05	0.000563	CcSEcCtD
Aprepitant—Nervous system disorder—Betamethasone—systemic lupus erythematosus	3.15e-05	0.000562	CcSEcCtD
Aprepitant—Nervous system disorder—Dexamethasone—systemic lupus erythematosus	3.15e-05	0.000562	CcSEcCtD
Aprepitant—Thrombocytopenia—Dexamethasone—systemic lupus erythematosus	3.15e-05	0.000561	CcSEcCtD
Aprepitant—Thrombocytopenia—Betamethasone—systemic lupus erythematosus	3.15e-05	0.000561	CcSEcCtD
Aprepitant—Tachycardia—Betamethasone—systemic lupus erythematosus	3.14e-05	0.000559	CcSEcCtD
Aprepitant—Tachycardia—Dexamethasone—systemic lupus erythematosus	3.14e-05	0.000559	CcSEcCtD
Aprepitant—Angioedema—Prednisone—systemic lupus erythematosus	3.13e-05	0.000558	CcSEcCtD
Aprepitant—Hypersensitivity—Cyclosporine—systemic lupus erythematosus	3.12e-05	0.000556	CcSEcCtD
Aprepitant—Dyspepsia—Triamcinolone—systemic lupus erythematosus	3.12e-05	0.000556	CcSEcCtD
Aprepitant—Erythema multiforme—Methotrexate—systemic lupus erythematosus	3.11e-05	0.000555	CcSEcCtD
Aprepitant—Dyspepsia—Methylprednisolone—systemic lupus erythematosus	3.11e-05	0.000554	CcSEcCtD
Aprepitant—Hyperhidrosis—Dexamethasone—systemic lupus erythematosus	3.11e-05	0.000554	CcSEcCtD
Aprepitant—Hyperhidrosis—Betamethasone—systemic lupus erythematosus	3.11e-05	0.000554	CcSEcCtD
Aprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CXCL12—systemic lupus erythematosus	3.11e-05	0.00538	CbGpPWpGaD
Aprepitant—TACR1—Peptide ligand-binding receptors—C3—systemic lupus erythematosus	3.1e-05	0.00537	CbGpPWpGaD
Aprepitant—Feeling abnormal—Hydrocortisone—systemic lupus erythematosus	3.1e-05	0.000552	CcSEcCtD
Aprepitant—Malaise—Prednisone—systemic lupus erythematosus	3.09e-05	0.000551	CcSEcCtD
Aprepitant—Eye disorder—Methotrexate—systemic lupus erythematosus	3.08e-05	0.000548	CcSEcCtD
Aprepitant—Gastrointestinal pain—Hydrocortisone—systemic lupus erythematosus	3.08e-05	0.000548	CcSEcCtD
Aprepitant—Syncope—Prednisone—systemic lupus erythematosus	3.08e-05	0.000548	CcSEcCtD
Aprepitant—Tinnitus—Methotrexate—systemic lupus erythematosus	3.07e-05	0.000547	CcSEcCtD
Aprepitant—Anorexia—Betamethasone—systemic lupus erythematosus	3.06e-05	0.000546	CcSEcCtD
Aprepitant—Anorexia—Dexamethasone—systemic lupus erythematosus	3.06e-05	0.000546	CcSEcCtD
Aprepitant—Urticaria—Prednisolone—systemic lupus erythematosus	3.06e-05	0.000545	CcSEcCtD
Aprepitant—Cardiac disorder—Methotrexate—systemic lupus erythematosus	3.06e-05	0.000545	CcSEcCtD
Aprepitant—Fatigue—Triamcinolone—systemic lupus erythematosus	3.05e-05	0.000544	CcSEcCtD
Aprepitant—Fatigue—Methylprednisolone—systemic lupus erythematosus	3.05e-05	0.000543	CcSEcCtD
Aprepitant—Hypersensitivity—Mycophenolate mofetil—systemic lupus erythematosus	3.04e-05	0.000542	CcSEcCtD
Aprepitant—Asthenia—Cyclosporine—systemic lupus erythematosus	3.04e-05	0.000541	CcSEcCtD
Aprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—JAK1—systemic lupus erythematosus	3.03e-05	0.00526	CbGpPWpGaD
Aprepitant—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—systemic lupus erythematosus	3.03e-05	0.00525	CbGpPWpGaD
Aprepitant—CYP2C9—Constitutive Androstane Receptor Pathway—RXRA—systemic lupus erythematosus	3.03e-05	0.00525	CbGpPWpGaD
Aprepitant—Pain—Triamcinolone—systemic lupus erythematosus	3.03e-05	0.00054	CcSEcCtD
Aprepitant—TACR1—Spinal Cord Injury—IFNG—systemic lupus erythematosus	3.02e-05	0.00524	CbGpPWpGaD
Aprepitant—Loss of consciousness—Prednisone—systemic lupus erythematosus	3.02e-05	0.000537	CcSEcCtD
Aprepitant—Hypotension—Betamethasone—systemic lupus erythematosus	3e-05	0.000535	CcSEcCtD
Aprepitant—Hypotension—Dexamethasone—systemic lupus erythematosus	3e-05	0.000535	CcSEcCtD
Aprepitant—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—systemic lupus erythematosus	3e-05	0.0052	CbGpPWpGaD
Aprepitant—Pruritus—Cyclosporine—systemic lupus erythematosus	3e-05	0.000534	CcSEcCtD
Aprepitant—Urticaria—Hydrocortisone—systemic lupus erythematosus	2.99e-05	0.000533	CcSEcCtD
Aprepitant—Angiopathy—Methotrexate—systemic lupus erythematosus	2.99e-05	0.000532	CcSEcCtD
Aprepitant—Immune system disorder—Methotrexate—systemic lupus erythematosus	2.97e-05	0.00053	CcSEcCtD
Aprepitant—Abdominal pain—Hydrocortisone—systemic lupus erythematosus	2.97e-05	0.00053	CcSEcCtD
Aprepitant—Body temperature increased—Hydrocortisone—systemic lupus erythematosus	2.97e-05	0.00053	CcSEcCtD
Aprepitant—Convulsion—Prednisone—systemic lupus erythematosus	2.97e-05	0.00053	CcSEcCtD
Aprepitant—Mediastinal disorder—Methotrexate—systemic lupus erythematosus	2.97e-05	0.000529	CcSEcCtD
Aprepitant—Asthenia—Mycophenolate mofetil—systemic lupus erythematosus	2.96e-05	0.000528	CcSEcCtD
Aprepitant—Hypertension—Prednisone—systemic lupus erythematosus	2.96e-05	0.000528	CcSEcCtD
Aprepitant—Chills—Methotrexate—systemic lupus erythematosus	2.96e-05	0.000526	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Betamethasone—systemic lupus erythematosus	2.93e-05	0.000522	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Dexamethasone—systemic lupus erythematosus	2.93e-05	0.000522	CcSEcCtD
Aprepitant—Pruritus—Mycophenolate mofetil—systemic lupus erythematosus	2.92e-05	0.000521	CcSEcCtD
Aprepitant—Arthralgia—Prednisone—systemic lupus erythematosus	2.92e-05	0.00052	CcSEcCtD
Aprepitant—Myalgia—Prednisone—systemic lupus erythematosus	2.92e-05	0.00052	CcSEcCtD
Aprepitant—Feeling abnormal—Triamcinolone—systemic lupus erythematosus	2.92e-05	0.00052	CcSEcCtD
Aprepitant—CYP3A7—Phase 1 - Functionalization of compounds—RXRA—systemic lupus erythematosus	2.92e-05	0.00505	CbGpPWpGaD
Aprepitant—Feeling abnormal—Methylprednisolone—systemic lupus erythematosus	2.91e-05	0.000519	CcSEcCtD
Aprepitant—Anxiety—Prednisone—systemic lupus erythematosus	2.91e-05	0.000519	CcSEcCtD
Aprepitant—Alopecia—Methotrexate—systemic lupus erythematosus	2.91e-05	0.000518	CcSEcCtD
Aprepitant—Insomnia—Betamethasone—systemic lupus erythematosus	2.91e-05	0.000518	CcSEcCtD
Aprepitant—Insomnia—Dexamethasone—systemic lupus erythematosus	2.91e-05	0.000518	CcSEcCtD
Aprepitant—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic lupus erythematosus	2.9e-05	0.000517	CcSEcCtD
Aprepitant—Diarrhoea—Cyclosporine—systemic lupus erythematosus	2.9e-05	0.000516	CcSEcCtD
Aprepitant—TACR1—Spinal Cord Injury—PTGS2—systemic lupus erythematosus	2.9e-05	0.00502	CbGpPWpGaD
Aprepitant—Gastrointestinal pain—Methylprednisolone—systemic lupus erythematosus	2.89e-05	0.000515	CcSEcCtD
Aprepitant—Paraesthesia—Betamethasone—systemic lupus erythematosus	2.89e-05	0.000514	CcSEcCtD
Aprepitant—Paraesthesia—Dexamethasone—systemic lupus erythematosus	2.89e-05	0.000514	CcSEcCtD
Aprepitant—Discomfort—Prednisone—systemic lupus erythematosus	2.89e-05	0.000514	CcSEcCtD
Aprepitant—Mental disorder—Methotrexate—systemic lupus erythematosus	2.89e-05	0.000514	CcSEcCtD
Aprepitant—Malnutrition—Methotrexate—systemic lupus erythematosus	2.87e-05	0.000511	CcSEcCtD
Aprepitant—Erythema—Methotrexate—systemic lupus erythematosus	2.87e-05	0.000511	CcSEcCtD
Aprepitant—TACR3—GPCR ligand binding—F2—systemic lupus erythematosus	2.85e-05	0.00494	CbGpPWpGaD
Aprepitant—Hypersensitivity—Prednisolone—systemic lupus erythematosus	2.84e-05	0.000506	CcSEcCtD
Aprepitant—Dyspepsia—Dexamethasone—systemic lupus erythematosus	2.83e-05	0.000504	CcSEcCtD
Aprepitant—Dyspepsia—Betamethasone—systemic lupus erythematosus	2.83e-05	0.000504	CcSEcCtD
Aprepitant—Diarrhoea—Mycophenolate mofetil—systemic lupus erythematosus	2.83e-05	0.000503	CcSEcCtD
Aprepitant—Urticaria—Triamcinolone—systemic lupus erythematosus	2.81e-05	0.000501	CcSEcCtD
Aprepitant—Urticaria—Methylprednisolone—systemic lupus erythematosus	2.81e-05	0.0005	CcSEcCtD
Aprepitant—Dysgeusia—Methotrexate—systemic lupus erythematosus	2.81e-05	0.0005	CcSEcCtD
Aprepitant—Body temperature increased—Triamcinolone—systemic lupus erythematosus	2.8e-05	0.000499	CcSEcCtD
Aprepitant—Dizziness—Cyclosporine—systemic lupus erythematosus	2.8e-05	0.000499	CcSEcCtD
Aprepitant—Oedema—Prednisone—systemic lupus erythematosus	2.8e-05	0.000499	CcSEcCtD
Aprepitant—Anaphylactic shock—Prednisone—systemic lupus erythematosus	2.8e-05	0.000499	CcSEcCtD
Aprepitant—Abdominal pain—Methylprednisolone—systemic lupus erythematosus	2.79e-05	0.000498	CcSEcCtD
Aprepitant—Decreased appetite—Dexamethasone—systemic lupus erythematosus	2.79e-05	0.000498	CcSEcCtD
Aprepitant—Decreased appetite—Betamethasone—systemic lupus erythematosus	2.79e-05	0.000498	CcSEcCtD
Aprepitant—Infection—Prednisone—systemic lupus erythematosus	2.78e-05	0.000496	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Betamethasone—systemic lupus erythematosus	2.78e-05	0.000494	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Dexamethasone—systemic lupus erythematosus	2.78e-05	0.000494	CcSEcCtD
Aprepitant—Back pain—Methotrexate—systemic lupus erythematosus	2.77e-05	0.000494	CcSEcCtD
Aprepitant—Hypersensitivity—Hydrocortisone—systemic lupus erythematosus	2.77e-05	0.000494	CcSEcCtD
Aprepitant—Fatigue—Betamethasone—systemic lupus erythematosus	2.77e-05	0.000494	CcSEcCtD
Aprepitant—Fatigue—Dexamethasone—systemic lupus erythematosus	2.77e-05	0.000494	CcSEcCtD
Aprepitant—CYP3A7—Biological oxidations—NAT2—systemic lupus erythematosus	2.76e-05	0.00479	CbGpPWpGaD
Aprepitant—TACR1—G alpha (q) signalling events—F2—systemic lupus erythematosus	2.76e-05	0.00478	CbGpPWpGaD
Aprepitant—Shock—Prednisone—systemic lupus erythematosus	2.75e-05	0.000491	CcSEcCtD
Aprepitant—Pain—Betamethasone—systemic lupus erythematosus	2.75e-05	0.00049	CcSEcCtD
Aprepitant—Pain—Dexamethasone—systemic lupus erythematosus	2.75e-05	0.00049	CcSEcCtD
Aprepitant—Nervous system disorder—Prednisone—systemic lupus erythematosus	2.75e-05	0.000489	CcSEcCtD
Aprepitant—TACR1—Spinal Cord Injury—CDKN1B—systemic lupus erythematosus	2.74e-05	0.00475	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—CXCL12—systemic lupus erythematosus	2.74e-05	0.00474	CbGpPWpGaD
Aprepitant—Tachycardia—Prednisone—systemic lupus erythematosus	2.73e-05	0.000487	CcSEcCtD
Aprepitant—Dizziness—Mycophenolate mofetil—systemic lupus erythematosus	2.73e-05	0.000487	CcSEcCtD
Aprepitant—CYP3A7—Metapathway biotransformation—NAT2—systemic lupus erythematosus	2.73e-05	0.00472	CbGpPWpGaD
Aprepitant—TACR1—Peptide ligand-binding receptors—F2—systemic lupus erythematosus	2.72e-05	0.00472	CbGpPWpGaD
Aprepitant—Skin disorder—Prednisone—systemic lupus erythematosus	2.72e-05	0.000484	CcSEcCtD
Aprepitant—Hyperhidrosis—Prednisone—systemic lupus erythematosus	2.71e-05	0.000482	CcSEcCtD
Aprepitant—Asthenia—Hydrocortisone—systemic lupus erythematosus	2.7e-05	0.000481	CcSEcCtD
Aprepitant—Vomiting—Cyclosporine—systemic lupus erythematosus	2.69e-05	0.00048	CcSEcCtD
Aprepitant—TACR1—Spinal Cord Injury—IL2—systemic lupus erythematosus	2.69e-05	0.00465	CbGpPWpGaD
Aprepitant—Rash—Cyclosporine—systemic lupus erythematosus	2.67e-05	0.000476	CcSEcCtD
Aprepitant—Anorexia—Prednisone—systemic lupus erythematosus	2.67e-05	0.000475	CcSEcCtD
Aprepitant—Dermatitis—Cyclosporine—systemic lupus erythematosus	2.67e-05	0.000475	CcSEcCtD
Aprepitant—Pruritus—Hydrocortisone—systemic lupus erythematosus	2.66e-05	0.000474	CcSEcCtD
Aprepitant—Ill-defined disorder—Methotrexate—systemic lupus erythematosus	2.66e-05	0.000474	CcSEcCtD
Aprepitant—Headache—Cyclosporine—systemic lupus erythematosus	2.65e-05	0.000473	CcSEcCtD
Aprepitant—Anaemia—Methotrexate—systemic lupus erythematosus	2.65e-05	0.000472	CcSEcCtD
Aprepitant—Feeling abnormal—Dexamethasone—systemic lupus erythematosus	2.65e-05	0.000472	CcSEcCtD
Aprepitant—Feeling abnormal—Betamethasone—systemic lupus erythematosus	2.65e-05	0.000472	CcSEcCtD
Aprepitant—Gastrointestinal pain—Betamethasone—systemic lupus erythematosus	2.63e-05	0.000468	CcSEcCtD
Aprepitant—Gastrointestinal pain—Dexamethasone—systemic lupus erythematosus	2.63e-05	0.000468	CcSEcCtD
Aprepitant—Vomiting—Mycophenolate mofetil—systemic lupus erythematosus	2.63e-05	0.000468	CcSEcCtD
Aprepitant—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—systemic lupus erythematosus	2.61e-05	0.00453	CbGpPWpGaD
Aprepitant—Hypersensitivity—Triamcinolone—systemic lupus erythematosus	2.61e-05	0.000465	CcSEcCtD
Aprepitant—Hypersensitivity—Methylprednisolone—systemic lupus erythematosus	2.6e-05	0.000464	CcSEcCtD
Aprepitant—Rash—Mycophenolate mofetil—systemic lupus erythematosus	2.6e-05	0.000464	CcSEcCtD
Aprepitant—Dermatitis—Mycophenolate mofetil—systemic lupus erythematosus	2.6e-05	0.000464	CcSEcCtD
Aprepitant—CYP3A5—Cytochrome P450 - arranged by substrate type—RXRA—systemic lupus erythematosus	2.6e-05	0.0045	CbGpPWpGaD
Aprepitant—Headache—Mycophenolate mofetil—systemic lupus erythematosus	2.59e-05	0.000461	CcSEcCtD
Aprepitant—Malaise—Methotrexate—systemic lupus erythematosus	2.59e-05	0.000461	CcSEcCtD
Aprepitant—Diarrhoea—Hydrocortisone—systemic lupus erythematosus	2.57e-05	0.000459	CcSEcCtD
Aprepitant—Urticaria—Dexamethasone—systemic lupus erythematosus	2.55e-05	0.000455	CcSEcCtD
Aprepitant—Urticaria—Betamethasone—systemic lupus erythematosus	2.55e-05	0.000455	CcSEcCtD
Aprepitant—TACR3—GPCR downstream signaling—RASGRP1—systemic lupus erythematosus	2.55e-05	0.00442	CbGpPWpGaD
Aprepitant—Musculoskeletal discomfort—Prednisone—systemic lupus erythematosus	2.55e-05	0.000454	CcSEcCtD
Aprepitant—Dizziness—Prednisolone—systemic lupus erythematosus	2.55e-05	0.000454	CcSEcCtD
Aprepitant—Asthenia—Triamcinolone—systemic lupus erythematosus	2.54e-05	0.000453	CcSEcCtD
Aprepitant—Abdominal pain—Betamethasone—systemic lupus erythematosus	2.54e-05	0.000453	CcSEcCtD
Aprepitant—Abdominal pain—Dexamethasone—systemic lupus erythematosus	2.54e-05	0.000453	CcSEcCtD
Aprepitant—Body temperature increased—Betamethasone—systemic lupus erythematosus	2.54e-05	0.000453	CcSEcCtD
Aprepitant—Body temperature increased—Dexamethasone—systemic lupus erythematosus	2.54e-05	0.000453	CcSEcCtD
Aprepitant—TACR1—Spinal Cord Injury—MMP9—systemic lupus erythematosus	2.54e-05	0.0044	CbGpPWpGaD
Aprepitant—TACR3—GPCR ligand binding—CCL2—systemic lupus erythematosus	2.54e-05	0.0044	CbGpPWpGaD
Aprepitant—Asthenia—Methylprednisolone—systemic lupus erythematosus	2.54e-05	0.000452	CcSEcCtD
Aprepitant—Insomnia—Prednisone—systemic lupus erythematosus	2.53e-05	0.000451	CcSEcCtD
Aprepitant—Nausea—Cyclosporine—systemic lupus erythematosus	2.52e-05	0.000448	CcSEcCtD
Aprepitant—Paraesthesia—Prednisone—systemic lupus erythematosus	2.51e-05	0.000448	CcSEcCtD
Aprepitant—Pruritus—Triamcinolone—systemic lupus erythematosus	2.51e-05	0.000447	CcSEcCtD
Aprepitant—Cough—Methotrexate—systemic lupus erythematosus	2.5e-05	0.000446	CcSEcCtD
Aprepitant—Pruritus—Methylprednisolone—systemic lupus erythematosus	2.5e-05	0.000446	CcSEcCtD
Aprepitant—Dizziness—Hydrocortisone—systemic lupus erythematosus	2.49e-05	0.000443	CcSEcCtD
Aprepitant—TACR3—Signaling by GPCR—CXCL12—systemic lupus erythematosus	2.49e-05	0.00431	CbGpPWpGaD
Aprepitant—Convulsion—Methotrexate—systemic lupus erythematosus	2.48e-05	0.000443	CcSEcCtD
Aprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—F2—systemic lupus erythematosus	2.47e-05	0.00427	CbGpPWpGaD
Aprepitant—Dyspepsia—Prednisone—systemic lupus erythematosus	2.46e-05	0.000439	CcSEcCtD
Aprepitant—Nausea—Mycophenolate mofetil—systemic lupus erythematosus	2.45e-05	0.000437	CcSEcCtD
Aprepitant—Chest pain—Methotrexate—systemic lupus erythematosus	2.44e-05	0.000435	CcSEcCtD
Aprepitant—Myalgia—Methotrexate—systemic lupus erythematosus	2.44e-05	0.000435	CcSEcCtD
Aprepitant—Arthralgia—Methotrexate—systemic lupus erythematosus	2.44e-05	0.000435	CcSEcCtD
Aprepitant—Decreased appetite—Prednisone—systemic lupus erythematosus	2.43e-05	0.000434	CcSEcCtD
Aprepitant—Rash—Prednisolone—systemic lupus erythematosus	2.43e-05	0.000433	CcSEcCtD
Aprepitant—TACR1—Peptide ligand-binding receptors—CCL2—systemic lupus erythematosus	2.43e-05	0.00421	CbGpPWpGaD
Aprepitant—Dermatitis—Prednisolone—systemic lupus erythematosus	2.43e-05	0.000432	CcSEcCtD
Aprepitant—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic lupus erythematosus	2.42e-05	0.000432	CcSEcCtD
Aprepitant—Diarrhoea—Methylprednisolone—systemic lupus erythematosus	2.42e-05	0.000431	CcSEcCtD
Aprepitant—Fatigue—Prednisone—systemic lupus erythematosus	2.41e-05	0.00043	CcSEcCtD
Aprepitant—Headache—Prednisolone—systemic lupus erythematosus	2.41e-05	0.00043	CcSEcCtD
Aprepitant—Discomfort—Methotrexate—systemic lupus erythematosus	2.41e-05	0.00043	CcSEcCtD
Aprepitant—Constipation—Prednisone—systemic lupus erythematosus	2.39e-05	0.000427	CcSEcCtD
Aprepitant—Vomiting—Hydrocortisone—systemic lupus erythematosus	2.39e-05	0.000426	CcSEcCtD
Aprepitant—Rash—Hydrocortisone—systemic lupus erythematosus	2.37e-05	0.000423	CcSEcCtD
Aprepitant—Dermatitis—Hydrocortisone—systemic lupus erythematosus	2.37e-05	0.000422	CcSEcCtD
Aprepitant—TACR1—GPCR ligand binding—CXCL12—systemic lupus erythematosus	2.37e-05	0.0041	CbGpPWpGaD
Aprepitant—Confusional state—Methotrexate—systemic lupus erythematosus	2.36e-05	0.00042	CcSEcCtD
Aprepitant—Headache—Hydrocortisone—systemic lupus erythematosus	2.36e-05	0.00042	CcSEcCtD
Aprepitant—Dizziness—Triamcinolone—systemic lupus erythematosus	2.34e-05	0.000417	CcSEcCtD
Aprepitant—Anaphylactic shock—Methotrexate—systemic lupus erythematosus	2.34e-05	0.000417	CcSEcCtD
Aprepitant—Dizziness—Methylprednisolone—systemic lupus erythematosus	2.34e-05	0.000416	CcSEcCtD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—systemic lupus erythematosus	2.33e-05	0.00404	CbGpPWpGaD
Aprepitant—Infection—Methotrexate—systemic lupus erythematosus	2.32e-05	0.000414	CcSEcCtD
Aprepitant—TACR3—Signaling by GPCR—RASGRP1—systemic lupus erythematosus	2.32e-05	0.00402	CbGpPWpGaD
Aprepitant—Feeling abnormal—Prednisone—systemic lupus erythematosus	2.31e-05	0.000411	CcSEcCtD
Aprepitant—Asthenia—Betamethasone—systemic lupus erythematosus	2.31e-05	0.000411	CcSEcCtD
Aprepitant—Asthenia—Dexamethasone—systemic lupus erythematosus	2.31e-05	0.000411	CcSEcCtD
Aprepitant—Nervous system disorder—Methotrexate—systemic lupus erythematosus	2.29e-05	0.000409	CcSEcCtD
Aprepitant—Thrombocytopenia—Methotrexate—systemic lupus erythematosus	2.29e-05	0.000408	CcSEcCtD
Aprepitant—Gastrointestinal pain—Prednisone—systemic lupus erythematosus	2.29e-05	0.000408	CcSEcCtD
Aprepitant—Nausea—Prednisolone—systemic lupus erythematosus	2.29e-05	0.000408	CcSEcCtD
Aprepitant—Pruritus—Dexamethasone—systemic lupus erythematosus	2.27e-05	0.000405	CcSEcCtD
Aprepitant—Pruritus—Betamethasone—systemic lupus erythematosus	2.27e-05	0.000405	CcSEcCtD
Aprepitant—Skin disorder—Methotrexate—systemic lupus erythematosus	2.27e-05	0.000405	CcSEcCtD
Aprepitant—Hyperhidrosis—Methotrexate—systemic lupus erythematosus	2.26e-05	0.000403	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—TLR9—systemic lupus erythematosus	2.25e-05	0.0039	CbGpPWpGaD
Aprepitant—Vomiting—Triamcinolone—systemic lupus erythematosus	2.25e-05	0.000401	CcSEcCtD
Aprepitant—Vomiting—Methylprednisolone—systemic lupus erythematosus	2.25e-05	0.0004	CcSEcCtD
Aprepitant—Nausea—Hydrocortisone—systemic lupus erythematosus	2.24e-05	0.000398	CcSEcCtD
Aprepitant—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—systemic lupus erythematosus	2.23e-05	0.00387	CbGpPWpGaD
Aprepitant—Rash—Triamcinolone—systemic lupus erythematosus	2.23e-05	0.000398	CcSEcCtD
Aprepitant—Dermatitis—Triamcinolone—systemic lupus erythematosus	2.23e-05	0.000398	CcSEcCtD
Aprepitant—Anorexia—Methotrexate—systemic lupus erythematosus	2.23e-05	0.000397	CcSEcCtD
Aprepitant—Rash—Methylprednisolone—systemic lupus erythematosus	2.23e-05	0.000397	CcSEcCtD
Aprepitant—Dermatitis—Methylprednisolone—systemic lupus erythematosus	2.23e-05	0.000397	CcSEcCtD
Aprepitant—Urticaria—Prednisone—systemic lupus erythematosus	2.22e-05	0.000396	CcSEcCtD
Aprepitant—Headache—Triamcinolone—systemic lupus erythematosus	2.22e-05	0.000395	CcSEcCtD
Aprepitant—Headache—Methylprednisolone—systemic lupus erythematosus	2.21e-05	0.000395	CcSEcCtD
Aprepitant—Body temperature increased—Prednisone—systemic lupus erythematosus	2.21e-05	0.000394	CcSEcCtD
Aprepitant—Abdominal pain—Prednisone—systemic lupus erythematosus	2.21e-05	0.000394	CcSEcCtD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUNB—systemic lupus erythematosus	2.21e-05	0.00383	CbGpPWpGaD
Aprepitant—Diarrhoea—Betamethasone—systemic lupus erythematosus	2.2e-05	0.000392	CcSEcCtD
Aprepitant—Diarrhoea—Dexamethasone—systemic lupus erythematosus	2.2e-05	0.000392	CcSEcCtD
Aprepitant—Hypotension—Methotrexate—systemic lupus erythematosus	2.19e-05	0.00039	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—P2RY12—systemic lupus erythematosus	2.18e-05	0.00378	CbGpPWpGaD
Aprepitant—Musculoskeletal discomfort—Methotrexate—systemic lupus erythematosus	2.13e-05	0.00038	CcSEcCtD
Aprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CCR5—systemic lupus erythematosus	2.13e-05	0.00369	CbGpPWpGaD
Aprepitant—Dizziness—Betamethasone—systemic lupus erythematosus	2.13e-05	0.000379	CcSEcCtD
Aprepitant—Dizziness—Dexamethasone—systemic lupus erythematosus	2.13e-05	0.000379	CcSEcCtD
Aprepitant—Insomnia—Methotrexate—systemic lupus erythematosus	2.12e-05	0.000377	CcSEcCtD
Aprepitant—CYP3A5—Phase 1 - Functionalization of compounds—RXRA—systemic lupus erythematosus	2.11e-05	0.00365	CbGpPWpGaD
Aprepitant—Nausea—Triamcinolone—systemic lupus erythematosus	2.1e-05	0.000375	CcSEcCtD
Aprepitant—Paraesthesia—Methotrexate—systemic lupus erythematosus	2.1e-05	0.000374	CcSEcCtD
Aprepitant—Nausea—Methylprednisolone—systemic lupus erythematosus	2.1e-05	0.000374	CcSEcCtD
Aprepitant—TACR1—Spinal Cord Injury—TGFB1—systemic lupus erythematosus	2.09e-05	0.00363	CbGpPWpGaD
Aprepitant—Dyspnoea—Methotrexate—systemic lupus erythematosus	2.09e-05	0.000372	CcSEcCtD
Aprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—C3—systemic lupus erythematosus	2.08e-05	0.00361	CbGpPWpGaD
Aprepitant—Somnolence—Methotrexate—systemic lupus erythematosus	2.08e-05	0.000371	CcSEcCtD
Aprepitant—Hypersensitivity—Prednisone—systemic lupus erythematosus	2.06e-05	0.000367	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—HIST2H2AC—systemic lupus erythematosus	2.06e-05	0.00357	CbGpPWpGaD
Aprepitant—Dyspepsia—Methotrexate—systemic lupus erythematosus	2.06e-05	0.000367	CcSEcCtD
Aprepitant—CYP1A2—Phase II conjugation—NAT2—systemic lupus erythematosus	2.06e-05	0.00356	CbGpPWpGaD
Aprepitant—Vomiting—Dexamethasone—systemic lupus erythematosus	2.04e-05	0.000364	CcSEcCtD
Aprepitant—Vomiting—Betamethasone—systemic lupus erythematosus	2.04e-05	0.000364	CcSEcCtD
Aprepitant—Decreased appetite—Methotrexate—systemic lupus erythematosus	2.03e-05	0.000362	CcSEcCtD
Aprepitant—Rash—Dexamethasone—systemic lupus erythematosus	2.03e-05	0.000361	CcSEcCtD
Aprepitant—Rash—Betamethasone—systemic lupus erythematosus	2.03e-05	0.000361	CcSEcCtD
Aprepitant—Dermatitis—Betamethasone—systemic lupus erythematosus	2.03e-05	0.000361	CcSEcCtD
Aprepitant—Dermatitis—Dexamethasone—systemic lupus erythematosus	2.03e-05	0.000361	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Methotrexate—systemic lupus erythematosus	2.02e-05	0.00036	CcSEcCtD
Aprepitant—Fatigue—Methotrexate—systemic lupus erythematosus	2.02e-05	0.000359	CcSEcCtD
Aprepitant—Headache—Dexamethasone—systemic lupus erythematosus	2.01e-05	0.000359	CcSEcCtD
Aprepitant—Headache—Betamethasone—systemic lupus erythematosus	2.01e-05	0.000359	CcSEcCtD
Aprepitant—CYP2C19—Cytochrome P450 - arranged by substrate type—RXRA—systemic lupus erythematosus	2.01e-05	0.00348	CbGpPWpGaD
Aprepitant—Asthenia—Prednisone—systemic lupus erythematosus	2.01e-05	0.000358	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—CSK—systemic lupus erythematosus	2.01e-05	0.00348	CbGpPWpGaD
Aprepitant—Pain—Methotrexate—systemic lupus erythematosus	2e-05	0.000356	CcSEcCtD
Aprepitant—TACR3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—systemic lupus erythematosus	2e-05	0.00346	CbGpPWpGaD
Aprepitant—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—systemic lupus erythematosus	2e-05	0.00346	CbGpPWpGaD
Aprepitant—CYP3A5—Biological oxidations—NAT2—systemic lupus erythematosus	2e-05	0.00346	CbGpPWpGaD
Aprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—systemic lupus erythematosus	2e-05	0.00346	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—P2RY12—systemic lupus erythematosus	1.99e-05	0.00344	CbGpPWpGaD
Aprepitant—Pruritus—Prednisone—systemic lupus erythematosus	1.98e-05	0.000353	CcSEcCtD
Aprepitant—TACR3—GPCR downstream signaling—JAK1—systemic lupus erythematosus	1.98e-05	0.00343	CbGpPWpGaD
Aprepitant—CYP3A5—Metapathway biotransformation—NAT2—systemic lupus erythematosus	1.97e-05	0.00341	CbGpPWpGaD
Aprepitant—TACR1—Spinal Cord Injury—TNF—systemic lupus erythematosus	1.96e-05	0.00339	CbGpPWpGaD
Aprepitant—Feeling abnormal—Methotrexate—systemic lupus erythematosus	1.93e-05	0.000344	CcSEcCtD
Aprepitant—TACR1—SIDS Susceptibility Pathways—EP300—systemic lupus erythematosus	1.93e-05	0.00334	CbGpPWpGaD
Aprepitant—Diarrhoea—Prednisone—systemic lupus erythematosus	1.92e-05	0.000341	CcSEcCtD
Aprepitant—Gastrointestinal pain—Methotrexate—systemic lupus erythematosus	1.91e-05	0.000341	CcSEcCtD
Aprepitant—Nausea—Dexamethasone—systemic lupus erythematosus	1.91e-05	0.00034	CcSEcCtD
Aprepitant—Nausea—Betamethasone—systemic lupus erythematosus	1.91e-05	0.00034	CcSEcCtD
Aprepitant—TACR3—GPCR downstream signaling—CCR5—systemic lupus erythematosus	1.88e-05	0.00325	CbGpPWpGaD
Aprepitant—Urticaria—Methotrexate—systemic lupus erythematosus	1.86e-05	0.000331	CcSEcCtD
Aprepitant—Dizziness—Prednisone—systemic lupus erythematosus	1.85e-05	0.00033	CcSEcCtD
Aprepitant—Body temperature increased—Methotrexate—systemic lupus erythematosus	1.85e-05	0.00033	CcSEcCtD
Aprepitant—Abdominal pain—Methotrexate—systemic lupus erythematosus	1.85e-05	0.00033	CcSEcCtD
Aprepitant—TACR3—GPCR downstream signaling—IL2RA—systemic lupus erythematosus	1.85e-05	0.0032	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—NCF2—systemic lupus erythematosus	1.84e-05	0.00318	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—C3—systemic lupus erythematosus	1.83e-05	0.00318	CbGpPWpGaD
Aprepitant—CYP2C9—Cytochrome P450 - arranged by substrate type—RXRA—systemic lupus erythematosus	1.83e-05	0.00318	CbGpPWpGaD
Aprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—F2—systemic lupus erythematosus	1.83e-05	0.00317	CbGpPWpGaD
Aprepitant—TACR1—SIDS Susceptibility Pathways—VEGFA—systemic lupus erythematosus	1.83e-05	0.00316	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—LYN—systemic lupus erythematosus	1.83e-05	0.00316	CbGpPWpGaD
Aprepitant—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—systemic lupus erythematosus	1.82e-05	0.00316	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—P2RY12—systemic lupus erythematosus	1.8e-05	0.00313	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—JAK1—systemic lupus erythematosus	1.8e-05	0.00312	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—SH2B3—systemic lupus erythematosus	1.79e-05	0.0031	CbGpPWpGaD
Aprepitant—Vomiting—Prednisone—systemic lupus erythematosus	1.78e-05	0.000317	CcSEcCtD
Aprepitant—Rash—Prednisone—systemic lupus erythematosus	1.77e-05	0.000314	CcSEcCtD
Aprepitant—Dermatitis—Prednisone—systemic lupus erythematosus	1.76e-05	0.000314	CcSEcCtD
Aprepitant—Headache—Prednisone—systemic lupus erythematosus	1.75e-05	0.000312	CcSEcCtD
Aprepitant—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—systemic lupus erythematosus	1.72e-05	0.00299	CbGpPWpGaD
Aprepitant—Hypersensitivity—Methotrexate—systemic lupus erythematosus	1.72e-05	0.000307	CcSEcCtD
Aprepitant—TACR3—Signaling by GPCR—CCR5—systemic lupus erythematosus	1.7e-05	0.00295	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—IL2RA—systemic lupus erythematosus	1.68e-05	0.00291	CbGpPWpGaD
Aprepitant—Asthenia—Methotrexate—systemic lupus erythematosus	1.68e-05	0.000299	CcSEcCtD
Aprepitant—TACR3—Signaling by GPCR—C3—systemic lupus erythematosus	1.67e-05	0.00289	CbGpPWpGaD
Aprepitant—Nausea—Prednisone—systemic lupus erythematosus	1.66e-05	0.000296	CcSEcCtD
Aprepitant—Pruritus—Methotrexate—systemic lupus erythematosus	1.66e-05	0.000295	CcSEcCtD
Aprepitant—CYP2C19—Phase 1 - Functionalization of compounds—RXRA—systemic lupus erythematosus	1.63e-05	0.00282	CbGpPWpGaD
Aprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic lupus erythematosus	1.63e-05	0.00282	CbGpPWpGaD
Aprepitant—TACR1—GPCR ligand binding—CCR5—systemic lupus erythematosus	1.62e-05	0.00281	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—F2—systemic lupus erythematosus	1.61e-05	0.00279	CbGpPWpGaD
Aprepitant—Diarrhoea—Methotrexate—systemic lupus erythematosus	1.6e-05	0.000285	CcSEcCtD
Aprepitant—TACR1—GPCR ligand binding—C3—systemic lupus erythematosus	1.58e-05	0.00275	CbGpPWpGaD
Aprepitant—TACR1—Spinal Cord Injury—IL6—systemic lupus erythematosus	1.58e-05	0.00273	CbGpPWpGaD
Aprepitant—CYP1A2—Cytochrome P450 - arranged by substrate type—RXRA—systemic lupus erythematosus	1.57e-05	0.00271	CbGpPWpGaD
Aprepitant—TACR1—SIDS Susceptibility Pathways—TNF—systemic lupus erythematosus	1.56e-05	0.00271	CbGpPWpGaD
Aprepitant—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—systemic lupus erythematosus	1.56e-05	0.0027	CbGpPWpGaD
Aprepitant—CYP3A7—Biological oxidations—RXRA—systemic lupus erythematosus	1.55e-05	0.00268	CbGpPWpGaD
Aprepitant—Dizziness—Methotrexate—systemic lupus erythematosus	1.55e-05	0.000276	CcSEcCtD
Aprepitant—CYP2C19—Biological oxidations—NAT2—systemic lupus erythematosus	1.54e-05	0.00268	CbGpPWpGaD
Aprepitant—CYP2C19—Metapathway biotransformation—NAT2—systemic lupus erythematosus	1.52e-05	0.00264	CbGpPWpGaD
Aprepitant—Vomiting—Methotrexate—systemic lupus erythematosus	1.49e-05	0.000265	CcSEcCtD
Aprepitant—CYP2C9—Phase 1 - Functionalization of compounds—RXRA—systemic lupus erythematosus	1.49e-05	0.00257	CbGpPWpGaD
Aprepitant—Rash—Methotrexate—systemic lupus erythematosus	1.48e-05	0.000263	CcSEcCtD
Aprepitant—Dermatitis—Methotrexate—systemic lupus erythematosus	1.47e-05	0.000263	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—CXCL12—systemic lupus erythematosus	1.47e-05	0.00254	CbGpPWpGaD
Aprepitant—Headache—Methotrexate—systemic lupus erythematosus	1.47e-05	0.000261	CcSEcCtD
Aprepitant—TACR3—Signaling by GPCR—F2—systemic lupus erythematosus	1.46e-05	0.00253	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—JUNB—systemic lupus erythematosus	1.44e-05	0.0025	CbGpPWpGaD
Aprepitant—CYP2C9—Biological oxidations—NAT2—systemic lupus erythematosus	1.41e-05	0.00244	CbGpPWpGaD
Aprepitant—TACR1—GPCR ligand binding—F2—systemic lupus erythematosus	1.39e-05	0.00241	CbGpPWpGaD
Aprepitant—Nausea—Methotrexate—systemic lupus erythematosus	1.39e-05	0.000248	CcSEcCtD
Aprepitant—CYP2C9—Metapathway biotransformation—NAT2—systemic lupus erythematosus	1.39e-05	0.00241	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—RASGRP1—systemic lupus erythematosus	1.37e-05	0.00237	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—CXCL12—systemic lupus erythematosus	1.34e-05	0.00232	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—PRL—systemic lupus erythematosus	1.33e-05	0.0023	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—CCL2—systemic lupus erythematosus	1.3e-05	0.00226	CbGpPWpGaD
Aprepitant—CYP1A2—Phase 1 - Functionalization of compounds—RXRA—systemic lupus erythematosus	1.27e-05	0.0022	CbGpPWpGaD
Aprepitant—TACR1—SIDS Susceptibility Pathways—IL6—systemic lupus erythematosus	1.26e-05	0.00219	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—RASGRP1—systemic lupus erythematosus	1.25e-05	0.00216	CbGpPWpGaD
Aprepitant—TACR1—GPCR ligand binding—CCL2—systemic lupus erythematosus	1.24e-05	0.00215	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—CXCL12—systemic lupus erythematosus	1.21e-05	0.0021	CbGpPWpGaD
Aprepitant—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—systemic lupus erythematosus	1.21e-05	0.00209	CbGpPWpGaD
Aprepitant—CYP1A2—Biological oxidations—NAT2—systemic lupus erythematosus	1.2e-05	0.00208	CbGpPWpGaD
Aprepitant—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—systemic lupus erythematosus	1.2e-05	0.00208	CbGpPWpGaD
Aprepitant—CYP1A2—Metapathway biotransformation—NAT2—systemic lupus erythematosus	1.19e-05	0.00206	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—TYK2—systemic lupus erythematosus	1.18e-05	0.00205	CbGpPWpGaD
Aprepitant—CYP2C19—Arachidonic acid metabolism—PTGS2—systemic lupus erythematosus	1.16e-05	0.002	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—RASGRP1—systemic lupus erythematosus	1.13e-05	0.00196	CbGpPWpGaD
Aprepitant—CYP3A5—Biological oxidations—RXRA—systemic lupus erythematosus	1.12e-05	0.00194	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—TLR9—systemic lupus erythematosus	1.1e-05	0.00191	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—IL2—systemic lupus erythematosus	1.08e-05	0.00188	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—P2RY12—systemic lupus erythematosus	1.07e-05	0.00185	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—JAK1—systemic lupus erythematosus	1.06e-05	0.00184	CbGpPWpGaD
Aprepitant—CYP2C9—Arachidonic acid metabolism—PTGS2—systemic lupus erythematosus	1.05e-05	0.00182	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—HIST2H2AC—systemic lupus erythematosus	1.01e-05	0.00174	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—CCR5—systemic lupus erythematosus	1.01e-05	0.00174	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—systemic lupus erythematosus	1e-05	0.00174	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—IL2RA—systemic lupus erythematosus	9.92e-06	0.00172	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—IL2—systemic lupus erythematosus	9.85e-06	0.00171	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—C3—systemic lupus erythematosus	9.84e-06	0.0017	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CSK—systemic lupus erythematosus	9.81e-06	0.0017	CbGpPWpGaD
Aprepitant—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—systemic lupus erythematosus	9.8e-06	0.0017	CbGpPWpGaD
Aprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—systemic lupus erythematosus	9.77e-06	0.00169	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—JAK1—systemic lupus erythematosus	9.67e-06	0.00168	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—systemic lupus erythematosus	9.62e-06	0.00167	CbGpPWpGaD
Aprepitant—CYP3A4—Biological oxidations—NAT2—systemic lupus erythematosus	9.29e-06	0.00161	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—CCR5—systemic lupus erythematosus	9.16e-06	0.00159	CbGpPWpGaD
Aprepitant—CYP3A4—Metapathway biotransformation—NAT2—systemic lupus erythematosus	9.16e-06	0.00159	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—systemic lupus erythematosus	9.11e-06	0.00158	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—systemic lupus erythematosus	9.11e-06	0.00158	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—IL2RA—systemic lupus erythematosus	9.03e-06	0.00156	CbGpPWpGaD
Aprepitant—CYP1A2—Arachidonic acid metabolism—PTGS2—systemic lupus erythematosus	9e-06	0.00156	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—NCF2—systemic lupus erythematosus	8.97e-06	0.00155	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—C3—systemic lupus erythematosus	8.96e-06	0.00155	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—systemic lupus erythematosus	8.92e-06	0.00155	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—LYN—systemic lupus erythematosus	8.91e-06	0.00154	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—JAK1—systemic lupus erythematosus	8.78e-06	0.00152	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—SH2B3—systemic lupus erythematosus	8.74e-06	0.00151	CbGpPWpGaD
Aprepitant—CYP2C19—Biological oxidations—RXRA—systemic lupus erythematosus	8.66e-06	0.0015	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—F2—systemic lupus erythematosus	8.64e-06	0.0015	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—systemic lupus erythematosus	8.41e-06	0.00146	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—CCR5—systemic lupus erythematosus	8.32e-06	0.00144	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—CD80—systemic lupus erythematosus	8.28e-06	0.00143	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—IL2RA—systemic lupus erythematosus	8.2e-06	0.00142	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—C3—systemic lupus erythematosus	8.13e-06	0.00141	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—systemic lupus erythematosus	8e-06	0.00139	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—EP300—systemic lupus erythematosus	8e-06	0.00139	CbGpPWpGaD
Aprepitant—CYP2C9—Biological oxidations—RXRA—systemic lupus erythematosus	7.89e-06	0.00137	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—F2—systemic lupus erythematosus	7.86e-06	0.00136	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—CCL2—systemic lupus erythematosus	7.7e-06	0.00133	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—systemic lupus erythematosus	7.58e-06	0.00131	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CXCL12—systemic lupus erythematosus	7.17e-06	0.00124	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—F2—systemic lupus erythematosus	7.14e-06	0.00124	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—JUNB—systemic lupus erythematosus	7.04e-06	0.00122	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—TYK2—systemic lupus erythematosus	6.99e-06	0.00121	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic lupus erythematosus	6.96e-06	0.00121	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—NOS3—systemic lupus erythematosus	6.86e-06	0.00119	CbGpPWpGaD
Aprepitant—CYP1A2—Biological oxidations—RXRA—systemic lupus erythematosus	6.75e-06	0.00117	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—RASGRP1—systemic lupus erythematosus	6.69e-06	0.00116	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—TNF—systemic lupus erythematosus	6.5e-06	0.00113	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—systemic lupus erythematosus	6.5e-06	0.00113	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—PRL—systemic lupus erythematosus	6.49e-06	0.00112	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—CCL2—systemic lupus erythematosus	6.36e-06	0.0011	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—CDKN1B—systemic lupus erythematosus	5.94e-06	0.00103	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—IL2—systemic lupus erythematosus	5.82e-06	0.00101	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—IL6—systemic lupus erythematosus	5.79e-06	0.001	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—TYK2—systemic lupus erythematosus	5.78e-06	0.001	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—MMP9—systemic lupus erythematosus	5.5e-06	0.000954	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—CDKN1A—systemic lupus erythematosus	5.49e-06	0.00095	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—IL2—systemic lupus erythematosus	5.29e-06	0.000917	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—EP300—systemic lupus erythematosus	5.22e-06	0.000904	CbGpPWpGaD
Aprepitant—CYP3A4—Biological oxidations—RXRA—systemic lupus erythematosus	5.21e-06	0.000902	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—JAK1—systemic lupus erythematosus	5.19e-06	0.000899	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—VEGFA—systemic lupus erythematosus	4.94e-06	0.000856	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CCR5—systemic lupus erythematosus	4.92e-06	0.000852	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—IL2RA—systemic lupus erythematosus	4.85e-06	0.000839	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—IL2—systemic lupus erythematosus	4.81e-06	0.000833	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—C3—systemic lupus erythematosus	4.8e-06	0.000832	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—NAT2—systemic lupus erythematosus	4.73e-06	0.000819	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—TGFB1—systemic lupus erythematosus	4.54e-06	0.000786	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—F2—systemic lupus erythematosus	4.22e-06	0.000731	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CD80—systemic lupus erythematosus	4.04e-06	0.000701	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CCL2—systemic lupus erythematosus	3.76e-06	0.000651	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—IL6—systemic lupus erythematosus	3.42e-06	0.000592	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—NAT2—systemic lupus erythematosus	3.42e-06	0.000592	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—TYK2—systemic lupus erythematosus	3.41e-06	0.000591	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—NOS3—systemic lupus erythematosus	3.35e-06	0.00058	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—RXRA—systemic lupus erythematosus	3.32e-06	0.000576	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—systemic lupus erythematosus	3.03e-06	0.000525	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CDKN1B—systemic lupus erythematosus	2.9e-06	0.000503	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—IL2—systemic lupus erythematosus	2.84e-06	0.000492	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—IL6—systemic lupus erythematosus	2.83e-06	0.00049	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—MMP9—systemic lupus erythematosus	2.69e-06	0.000466	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CDKN1A—systemic lupus erythematosus	2.68e-06	0.000464	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—RXRA—systemic lupus erythematosus	2.65e-06	0.000459	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—NAT2—systemic lupus erythematosus	2.64e-06	0.000458	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—RXRA—systemic lupus erythematosus	2.59e-06	0.000449	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—EP300—systemic lupus erythematosus	2.55e-06	0.000442	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—VEGFA—systemic lupus erythematosus	2.41e-06	0.000418	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—NAT2—systemic lupus erythematosus	2.41e-06	0.000417	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—TGFB1—systemic lupus erythematosus	2.22e-06	0.000384	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—systemic lupus erythematosus	2.1e-06	0.000364	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—NAT2—systemic lupus erythematosus	2.06e-06	0.000356	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—RXRA—systemic lupus erythematosus	1.91e-06	0.000332	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—systemic lupus erythematosus	1.91e-06	0.000332	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—ALB—systemic lupus erythematosus	1.89e-06	0.000327	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—ALB—systemic lupus erythematosus	1.72e-06	0.000298	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PPARG—systemic lupus erythematosus	1.67e-06	0.00029	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—IL6—systemic lupus erythematosus	1.67e-06	0.000289	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—systemic lupus erythematosus	1.65e-06	0.000286	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—systemic lupus erythematosus	1.64e-06	0.000283	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—NAT2—systemic lupus erythematosus	1.59e-06	0.000275	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—systemic lupus erythematosus	1.51e-06	0.000261	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—ALB—systemic lupus erythematosus	1.5e-06	0.000261	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—RXRA—systemic lupus erythematosus	1.48e-06	0.000256	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—ALB—systemic lupus erythematosus	1.47e-06	0.000255	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—NOS3—systemic lupus erythematosus	1.44e-06	0.000249	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—EP300—systemic lupus erythematosus	1.37e-06	0.000238	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—RXRA—systemic lupus erythematosus	1.35e-06	0.000234	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PTGS2—systemic lupus erythematosus	1.32e-06	0.000228	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—systemic lupus erythematosus	1.29e-06	0.000223	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—EP300—systemic lupus erythematosus	1.25e-06	0.000217	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PPARG—systemic lupus erythematosus	1.21e-06	0.000209	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—RXRA—systemic lupus erythematosus	1.15e-06	0.0002	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—EP300—systemic lupus erythematosus	1.09e-06	0.00019	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—ALB—systemic lupus erythematosus	1.09e-06	0.000188	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—EP300—systemic lupus erythematosus	1.07e-06	0.000185	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—NOS3—systemic lupus erythematosus	1.04e-06	0.00018	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PTGS2—systemic lupus erythematosus	9.51e-07	0.000165	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PPARG—systemic lupus erythematosus	9.35e-07	0.000162	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—RXRA—systemic lupus erythematosus	8.9e-07	0.000154	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PPARG—systemic lupus erythematosus	8.52e-07	0.000148	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—ALB—systemic lupus erythematosus	8.4e-07	0.000146	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—NOS3—systemic lupus erythematosus	8.04e-07	0.000139	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—EP300—systemic lupus erythematosus	7.91e-07	0.000137	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—ALB—systemic lupus erythematosus	7.66e-07	0.000133	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PTGS2—systemic lupus erythematosus	7.35e-07	0.000127	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—NOS3—systemic lupus erythematosus	7.33e-07	0.000127	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PPARG—systemic lupus erythematosus	7.28e-07	0.000126	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PTGS2—systemic lupus erythematosus	6.7e-07	0.000116	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—ALB—systemic lupus erythematosus	6.55e-07	0.000113	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—NOS3—systemic lupus erythematosus	6.26e-07	0.000109	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—EP300—systemic lupus erythematosus	6.12e-07	0.000106	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PTGS2—systemic lupus erythematosus	5.73e-07	9.93e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PPARG—systemic lupus erythematosus	5.62e-07	9.74e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—EP300—systemic lupus erythematosus	5.58e-07	9.66e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—ALB—systemic lupus erythematosus	5.05e-07	8.76e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—NOS3—systemic lupus erythematosus	4.83e-07	8.38e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—EP300—systemic lupus erythematosus	4.77e-07	8.26e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PTGS2—systemic lupus erythematosus	4.42e-07	7.66e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—EP300—systemic lupus erythematosus	3.68e-07	6.37e-05	CbGpPWpGaD
